Four months after a buyout approach collapsed, the heat-treatment specialist is relying on aerospace Demand and plant closures to make its own case to shareholders.

Bodycote (LSE:BOY) spent the early summer of 2026 as a Takeover target and the rest of it proving it can stand on its own. The Macclesfield-based FTSE 250 provider of heat treatment and specialist thermal processing services saw its shares swing sharply when Apollo made, and then abandoned, a cash approach. Since then the company has leaned on solid half-year numbers and the progress of its restructuring programme to rebuild confidence.

The Apollo Episode

On 22 May, Bodycote confirmed it had received a conditional proposal from Apollo Management X at 885 pence per share in cash, with shareholders also keeping a 16.1 pence final Dividend for 2025. The shares jumped 19% to 829.5 pence that day. Two weeks later, on 5 June, Apollo said it did not intend to make a firm offer, and the shares closed 13% lower at 715.5 pence.

The board responded by reiterating confidence in its strategy, pointing to a positive start to trading highlighted at its annual meeting in late May. At that update, core Revenue was up 9% at constant currency over the first four months, led by the Specialist Technologies business, while automotive volumes were weaker.

Half-Year Results Back the Standalone Plan

Bodycote's interim results on 28 July supported that message. Core organic revenue growth reached 9.6%, with core revenues rising to £372.0 million from £336.6 million. Adjusted Basic Earnings Per Share increased 18.3% to 25.2 pence. Aerospace and defence revenue grew 25% on an organic basis and industrial gas turbines 11%, while automotive fell 4%, reflecting structural challenges in Western Europe. Specialist Technologies grew 16.7% organically and now makes up half of divisional revenue.

The company maintained its full-year forecast despite geopolitical and macroeconomic uncertainty, and reported adjusted operating margins of around 16% at both the core and group levels.

Optimise, Perform, Grow

Much of the improvement is self-help. Under the Optimise programme, Bodycote has completed 27 of the 31 planned plant closures and consolidations, generating around £31 million of profit improvement. Shrinking the network of lower-return sites is intended to shift the mix towards higher-value work for aerospace, defence and energy clients, where the specialist processes involved tend to carry higher technical barriers.

The group is also investing. It acquired Spectrum Thermal Processing in January for around £6 million, and Capital Expenditure in the first half was £33.5 million, including greenfield sites in South Korea and Mexico due to open in 2027. Shareholder returns continued, with £27.5 million paid in dividends and £17.8 million spent on Buybacks in the half, the latter at an average of around 680 pence per share.

What the Market Is Weighing

The central question for investors is whether management can close the gap between the share price and the 885 pence level Apollo had been prepared to discuss. Continued double-digit growth in aerospace and defence, combined with the completion of the remaining plant exits, would support the argument that Bodycote's earnings are on a structurally higher footing.

Risks remain, notably the weakness in European automotive production and softer US industrial volumes, which the company has acknowledged. Management has also said it expects core organic growth to moderate in the second half after a healthy first six months.

The next update is expected with a pre-close trading statement around the year end, ahead of full-year results in early 2027, when investors will assess whether margin targets have been met and how capital will be allocated.